Manuel Pombo-Suarez1, Carlos Sanchez-Piedra2, Blanca Garcia-Magallón3, Ana Pérez-Gómez4, Sara Manrique-Arija5, Raquel Martín-Doménech6, María Colazo7, Cristina Campos8, José Campos9, Javier Del Pino-Montes10, Maria J Arteaga11, Luis Cea-Calvo11, Federico Díaz-González12, Juan J Gómez-Reino13. 1. Department of Rheumatology, Hospital Universitario de Santiago de Compostela, Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain. mpombosuarez@ser.es. 2. Clinical Research Unit, Spanish Society of Rheumatology (SER), Madrid, Spain. 3. Department of Rheumatology, Hospital San Jorge, Huesca, Spain. 4. Department of Rheumatology, Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. 5. Department of Rheumatology, Hospital Carlos Haya, Málaga, Spain. 6. Department of Rheumatology, Hospital de Elda, Alicante, Spain. 7. Department of Rheumatology, Hospital Universitario de Burgos, Burgos, Spain. 8. Department of Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain. 9. Department of Rheumatology, Hospital Puerta de Hierro, Madrid, Spain. 10. Department of Rheumatology, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. 11. Medical Affairs Department, MSD Spain, Madrid, Spain. 12. Department of Rheumatology, Hospital Universitario de Canarias, Sta Cruz de Tenerife, Spain. 13. Department of Rheumatology, Hospital Universitario de Santiago de Compostela, Rúa da Choupana, s/n, 15706 Santiago de Compostela, A Coruña, Spain.
Abstract
BACKGROUND: Retention of biological treatment provides a marker of drug effectiveness and patient satisfaction. Retention of golimumab was high in clinical trial extensions and real-world studies up to 5 years in patients with immune-mediated rheumatic diseases. OBJECTIVE: To assess the probability of real-world long-term retention of treatment with golimumab up to 7 years after treatment initiation. METHODS: This retrospective noninterventional study involved analysis of the Spanish biological drugs registry, BIOBADASER. Adults who had ever received golimumab for rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA), and had initiated it > 6 months before the analysis date, were included. RESULTS: Among 685 patients (28.5% RA, 42.9% SpA, 28.6% PsA), the overall probability of retention of golimumab treatment since initiation was 71.7% (95% confidence interval 68.1-74.9) at year 1, 60.5% (56.5-64.2%) at year 2, 55.6% (51.5-59.5%) at year 3, 50.6% (46.2-54.8%) at year 4, 45.1% (40.1-50.0%) at year 5, 44.2% (39.0-49.3) at year 6, and 39.5% (32.8-46.2) at year 7. Retention was greater in patients with axial SpA or PsA versus RA (p < 0.001) and when golimumab was used as first-line treatment versus third or later lines (p < 0.001). Factors associated with greater golimumab retention in Cox regression included use as first-line biological therapy, having axial SpA or PsA rather than RA, and concomitant methotrexate therapy. Steroids were associated with lower retention. CONCLUSION: In this real-world study of RA, axial SpA, and PsA patients, the retention rate of golimumab was 39.5% at year 7. Key Points • Retention of biological treatment provides a marker of drug effectiveness and patient satisfaction. • This real-world study of 685 patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) showed that golimumab treatment had a retention rate up to 39.5% at year 7. • Greater golimumab retention was associated with use as first-line biological therapy, having axial SpA or PsA rather than RA, and concomitant methotrexate therapy.
BACKGROUND: Retention of biological treatment provides a marker of drug effectiveness and patient satisfaction. Retention of golimumab was high in clinical trial extensions and real-world studies up to 5 years in patients with immune-mediated rheumatic diseases. OBJECTIVE: To assess the probability of real-world long-term retention of treatment with golimumab up to 7 years after treatment initiation. METHODS: This retrospective noninterventional study involved analysis of the Spanish biological drugs registry, BIOBADASER. Adults who had ever received golimumab for rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA), and had initiated it > 6 months before the analysis date, were included. RESULTS: Among 685 patients (28.5% RA, 42.9% SpA, 28.6% PsA), the overall probability of retention of golimumab treatment since initiation was 71.7% (95% confidence interval 68.1-74.9) at year 1, 60.5% (56.5-64.2%) at year 2, 55.6% (51.5-59.5%) at year 3, 50.6% (46.2-54.8%) at year 4, 45.1% (40.1-50.0%) at year 5, 44.2% (39.0-49.3) at year 6, and 39.5% (32.8-46.2) at year 7. Retention was greater in patients with axial SpA or PsA versus RA (p < 0.001) and when golimumab was used as first-line treatment versus third or later lines (p < 0.001). Factors associated with greater golimumab retention in Cox regression included use as first-line biological therapy, having axial SpA or PsA rather than RA, and concomitant methotrexate therapy. Steroids were associated with lower retention. CONCLUSION: In this real-world study of RA, axial SpA, and PsA patients, the retention rate of golimumab was 39.5% at year 7. Key Points • Retention of biological treatment provides a marker of drug effectiveness and patient satisfaction. • This real-world study of 685 patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA) showed that golimumab treatment had a retention rate up to 39.5% at year 7. • Greater golimumab retention was associated with use as first-line biological therapy, having axial SpA or PsA rather than RA, and concomitant methotrexate therapy.
Authors: Jonathan Kay; Roy Fleischmann; Edward Keystone; Elizabeth C Hsia; Benjamin Hsu; Yiying Zhou; Neil Goldstein; Jürgen Braun Journal: J Rheumatol Date: 2016-11-01 Impact factor: 4.666
Authors: Maria V Hernandez; Carlos Sanchez-Piedra; Blanca Garcia-Magallon; Eduardo Cuende; Javier Manero; Cristina Campos-Fernandez; Raquel Martin-Domenech; Javier Del Pino-Montes; Sara Manrique; Maria C Castro-Villegas; Dolores Ruiz-Montesinos; Fernando Sanchez-Alonso; Federico Diaz-Gonzalez; Luis Cea-Calvo; Juan J Gómez-Reino Journal: Rheumatol Int Date: 2018-10-24 Impact factor: 2.631
Authors: Edward C Keystone; Mark C Genovese; Stephen Hall; Sang-Cheol Bae; Chenglong Han; Timothy A Gathany; Stephen Xu; Yiying Zhou; Jocelyn H Leu; Elizabeth C Hsia Journal: J Rheumatol Date: 2015-12-15 Impact factor: 4.666
Authors: Atul Deodhar; Jürgen Braun; Robert D Inman; Désirée van der Heijde; Yiying Zhou; Stephen Xu; Chenglong Han; Benjamin Hsu Journal: Ann Rheum Dis Date: 2014-11-11 Impact factor: 19.103
Authors: Josef S Smolen; Jonathan Kay; Mittie Doyle; Robert Landewé; Eric L Matteson; Norman Gaylis; Jürgen Wollenhaupt; Frederick T Murphy; Stephen Xu; Yiying Zhou; Elizabeth C Hsia Journal: Arthritis Res Ther Date: 2015-01-22 Impact factor: 5.156
Authors: Karin Luttropp; Mary Dozier; Nahila Justo; Freddy Cornillie; Sumesh Kachroo; Marinella Govoni; Stina Salomonsson; Christopher M Black; Ahmed Khalifa Journal: BMJ Open Date: 2019-05-28 Impact factor: 2.692
Authors: Maria Sole Chimenti; Paola Conigliaro; Francesco Caso; Luisa Costa; Augusta Ortolan; Paola Triggianese; Marco Tasso; Giulia Lavinia Fonti; Maria Grazia Lorenzin; Roberto Perricone; Roberta Ramonda Journal: Clin Rheumatol Date: 2021-08-19 Impact factor: 3.650